Summary

The global Plasma-derived Therapies market size was US$ 37710 million in 2025 and is forecast to reach a readjusted size of US$ 62130 million by 2032 with a CAGR of 7.5% during the forecast period 2026-2032.
Plasma-derived Therapies: These are medicinal products that are manufactured from human plasma, the liquid component of blood. Plasma contains important proteins, clotting factors, and antibodies that can be processed and concentrated to create products used in various medical treatments. PDPs are essential for treating conditions such as hemophilia, immune deficiencies, and certain autoimmune diseases.
Driver of the Plasma-derived Therapies Market:
One of the main drivers of the plasma-derived therapies market is the increasing prevalence of rare and chronic diseases, such as hemophilia, primary immunodeficiency disorders, and autoimmune diseases. These conditions require ongoing treatment with plasma-derived products like clotting factors, immunoglobulins, and albumin. The growing awareness and diagnosis rates of such diseases, along with advancements in plasma collection and fractionation technologies, have contributed to a higher demand for these therapies. Additionally, increasing investments in healthcare infrastructure and government support in emerging markets are fueling market growth.
Challenge of the Plasma-derived Therapies Market:
A key challenge in this market is the complex and costly process of plasma collection and product manufacturing. Plasma-derived therapies require large volumes of plasma, which can only be obtained through human donors. The stringent regulations surrounding plasma collection, donor screening, and testing to ensure safety make the process time-consuming and expensive. Furthermore, any disruption in plasma supply chains, such as those caused by geopolitical issues or pandemics, can lead to shortages and impact treatment availability.
The outbreak of COVID-19 pandemic has led to decrease in number of blood donations and plasma collections, which hampers the market growth as it leads to shortage in raw material supply.
The classification of Plasma-derived Therapies includes Immune Globulin, Coagulation Factor, Albumin and Other. In 2023, Immune Globulin accounted for a share of 51% in the global Plasma-derived Therapies market.
North America is the largest consumption place, with a revenue market share nearly 40% in 2023. Following North America, Europe is the second largest consumption place with the revenue market share of 24 %; China is also an important sales region for the Plasma-derived Therapies.
The global Plasma-derived Therapies market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032.
Market Segmentation
By Company:
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics
Segment by Type
Immune Globulin
Coagulation Factor
Albumin
Other
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
Macro-Region
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Markets
North America
Europe
China
Japan
(Additional regions can be customized based on client needs.)
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term)
Chapter 2: Quantitative analysis of Plasma-derived Therapies market size and growth potential at global, regional, and country levels
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus)
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities
Chapter 6: Regional revenue breakdown by company, type, application and customer
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Plasma-derived Therapies value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size and Growth by Type: 2021 vs 2025 vs 2032
1.2.2 Immune Globulin
1.2.3 Coagulation Factor
1.2.4 Albumin
1.2.5 Other
1.3 Market by Application
1.3.1 Global Market Share by Application: 2021 vs 2025 vs 2032
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Plasma-derived Therapies Market Perspective (2021-2032)
2.2 Global Market Size by Region: 2021 vs 2025 vs 2032
2.3 Global Plasma-derived Therapies Market Share by Revenue, by Region (2021-2026)
2.4 Global Plasma-derived Therapies Revenue Forecast by Region (2027-2032)
2.5 Major Regions and Emerging Markets Analysis
2.5.1 North America Plasma-derived Therapies Market Size and Prospective (2021-2032)
2.5.2 Europe Plasma-derived Therapies Market Size and Prospective (2021-2032)
2.5.3 China Plasma-derived Therapies Market Size and Prospective (2021-2032)
2.5.4 Japan Plasma-derived Therapies Market Size and Prospective (2021-2032)
3 Breakdown Data by Type
3.1 Global Plasma-derived Therapies Historical Market Size by Type (2021-2026)
3.2 Global Plasma-derived Therapies Forecasted Market Size by Type (2027-2032)
3.3 Representative Players for Different Types of Plasma-derived Therapies
4 Breakdown Data by Application
4.1 Global Plasma-derived Therapies Historical Market Size by Application (2021-2026)
4.2 Global Plasma-derived Therapies Forecasted Market Size by Application (2027-2032)
4.3 New Sources of Growth in Plasma-derived Therapies Applications
5 Competitive Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Plasma-derived Therapies Players by Revenue (2021-2026)
5.1.2 Global Plasma-derived Therapies Market Share by Revenue, by Players (2021-2026)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Plasma-derived Therapies Revenue
5.4 Global Plasma-derived Therapies Market Concentration Analysis
5.4.1 Global Plasma-derived Therapies Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Plasma-derived Therapies Revenue in 2025
5.5 Global Key Players of Plasma-derived Therapies Head Offices and Areas Served
5.6 Global Key Players of Plasma-derived Therapies, Product and Application
5.7 Global Key Players of Plasma-derived Therapies, Date of Entry into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Plasma-derived Therapies Revenue by Company (2021-2026)
6.1.2 North America Market Size by Type
6.1.2.1 North America Plasma-derived Therapies Market Size by Type (2021-2026)
6.1.2.2 North America Plasma-derived Therapies Market Share by Type (2021-2026)
6.1.3 North America Market Size by Application
6.1.3.1 North America Plasma-derived Therapies Market Size by Application (2021-2026)
6.1.3.2 North America Plasma-derived Therapies Market Share by Application (2021-2026)
6.1.4 North America Plasma-derived Therapies Major Customers
6.1.5 North America Market Trends and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Plasma-derived Therapies Revenue by Company (2021-2026)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Plasma-derived Therapies Market Size by Type (2021-2026)
6.2.2.2 Europe Plasma-derived Therapies Market Share by Type (2021-2026)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Plasma-derived Therapies Market Size by Application (2021-2026)
6.2.3.2 Europe Plasma-derived Therapies Market Share by Application (2021-2026)
6.2.4 Europe Plasma-derived Therapies Major Customers
6.2.5 Europe Market Trends and Opportunities
6.3 China Market: Players, Segments, Downstream and Major Customers
6.3.1 China Plasma-derived Therapies Revenue by Company (2021-2026)
6.3.2 China Market Size by Type
6.3.2.1 China Plasma-derived Therapies Market Size by Type (2021-2026)
6.3.2.2 China Plasma-derived Therapies Market Share by Type (2021-2026)
6.3.3 China Market Size by Application
6.3.3.1 China Plasma-derived Therapies Market Size by Application (2021-2026)
6.3.3.2 China Plasma-derived Therapies Market Share by Application (2021-2026)
6.3.4 China Plasma-derived Therapies Major Customers
6.3.5 China Market Trends and Opportunities
6.4 Japan Market: Players, Segments, Downstream and Major Customers
6.4.1 Japan Plasma-derived Therapies Revenue by Company (2021-2026)
6.4.2 Japan Market Size by Type
6.4.2.1 Japan Plasma-derived Therapies Market Size by Type (2021-2026)
6.4.2.2 Japan Plasma-derived Therapies Market Share by Type (2021-2026)
6.4.3 Japan Market Size by Application
6.4.3.1 Japan Plasma-derived Therapies Market Size by Application (2021-2026)
6.4.3.2 Japan Plasma-derived Therapies Market Share by Application (2021-2026)
6.4.4 Japan Plasma-derived Therapies Major Customers
6.4.5 Japan Market Trends and Opportunities
7 Key Player Profiles
7.1 Takeda
7.1.1 Takeda Company Details
7.1.2 Takeda Business Overview
7.1.3 Takeda Plasma-derived Therapies Introduction
7.1.4 Takeda Revenue in Plasma-derived Therapies Business (2021-2026)
7.1.5 Takeda Recent Development
7.2 CSL
7.2.1 CSL Company Details
7.2.2 CSL Business Overview
7.2.3 CSL Plasma-derived Therapies Introduction
7.2.4 CSL Revenue in Plasma-derived Therapies Business (2021-2026)
7.2.5 CSL Recent Development
7.3 Grifols
7.3.1 Grifols Company Details
7.3.2 Grifols Business Overview
7.3.3 Grifols Plasma-derived Therapies Introduction
7.3.4 Grifols Revenue in Plasma-derived Therapies Business (2021-2026)
7.3.5 Grifols Recent Development
7.4 Octapharma
7.4.1 Octapharma Company Details
7.4.2 Octapharma Business Overview
7.4.3 Octapharma Plasma-derived Therapies Introduction
7.4.4 Octapharma Revenue in Plasma-derived Therapies Business (2021-2026)
7.4.5 Octapharma Recent Development
7.5 Kedrion
7.5.1 Kedrion Company Details
7.5.2 Kedrion Business Overview
7.5.3 Kedrion Plasma-derived Therapies Introduction
7.5.4 Kedrion Revenue in Plasma-derived Therapies Business (2021-2026)
7.5.5 Kedrion Recent Development
7.6 LFB Group
7.6.1 LFB Group Company Details
7.6.2 LFB Group Business Overview
7.6.3 LFB Group Plasma-derived Therapies Introduction
7.6.4 LFB Group Revenue in Plasma-derived Therapies Business (2021-2026)
7.6.5 LFB Group Recent Development
7.7 Biotest
7.7.1 Biotest Company Details
7.7.2 Biotest Business Overview
7.7.3 Biotest Plasma-derived Therapies Introduction
7.7.4 Biotest Revenue in Plasma-derived Therapies Business (2021-2026)
7.7.5 Biotest Recent Development
7.8 BPL
7.8.1 BPL Company Details
7.8.2 BPL Business Overview
7.8.3 BPL Plasma-derived Therapies Introduction
7.8.4 BPL Revenue in Plasma-derived Therapies Business (2021-2026)
7.8.5 BPL Recent Development
7.9 RAAS
7.9.1 RAAS Company Details
7.9.2 RAAS Business Overview
7.9.3 RAAS Plasma-derived Therapies Introduction
7.9.4 RAAS Revenue in Plasma-derived Therapies Business (2021-2026)
7.9.5 RAAS Recent Development
7.10 CBPO
7.10.1 CBPO Company Details
7.10.2 CBPO Business Overview
7.10.3 CBPO Plasma-derived Therapies Introduction
7.10.4 CBPO Revenue in Plasma-derived Therapies Business (2021-2026)
7.10.5 CBPO Recent Development
7.11 Hualan Bio
7.11.1 Hualan Bio Company Details
7.11.2 Hualan Bio Business Overview
7.11.3 Hualan Bio Plasma-derived Therapies Introduction
7.11.4 Hualan Bio Revenue in Plasma-derived Therapies Business (2021-2026)
7.11.5 Hualan Bio Recent Development
7.12 Tiantan Bio
7.12.1 Tiantan Bio Company Details
7.12.2 Tiantan Bio Business Overview
7.12.3 Tiantan Bio Plasma-derived Therapies Introduction
7.12.4 Tiantan Bio Revenue in Plasma-derived Therapies Business (2021-2026)
7.12.5 Tiantan Bio Recent Development
7.13 Shuanglin Bio
7.13.1 Shuanglin Bio Company Details
7.13.2 Shuanglin Bio Business Overview
7.13.3 Shuanglin Bio Plasma-derived Therapies Introduction
7.13.4 Shuanglin Bio Revenue in Plasma-derived Therapies Business (2021-2026)
7.13.5 Shuanglin Bio Recent Development
7.14 Boya Bio
7.14.1 Boya Bio Company Details
7.14.2 Boya Bio Business Overview
7.14.3 Boya Bio Plasma-derived Therapies Introduction
7.14.4 Boya Bio Revenue in Plasma-derived Therapies Business (2021-2026)
7.14.5 Boya Bio Recent Development
7.15 Yuanda Shuyang
7.15.1 Yuanda Shuyang Company Details
7.15.2 Yuanda Shuyang Business Overview
7.15.3 Yuanda Shuyang Plasma-derived Therapies Introduction
7.15.4 Yuanda Shuyang Revenue in Plasma-derived Therapies Business (2021-2026)
7.15.5 Yuanda Shuyang Recent Development
7.16 Weiguang Bio
7.16.1 Weiguang Bio Company Details
7.16.2 Weiguang Bio Business Overview
7.16.3 Weiguang Bio Plasma-derived Therapies Introduction
7.16.4 Weiguang Bio Revenue in Plasma-derived Therapies Business (2021-2026)
7.16.5 Weiguang Bio Recent Development
7.17 Nanyue Bio
7.17.1 Nanyue Bio Company Details
7.17.2 Nanyue Bio Business Overview
7.17.3 Nanyue Bio Plasma-derived Therapies Introduction
7.17.4 Nanyue Bio Revenue in Plasma-derived Therapies Business (2021-2026)
7.17.5 Nanyue Bio Recent Development
7.18 KM Biologics
7.18.1 KM Biologics Company Details
7.18.2 KM Biologics Business Overview
7.18.3 KM Biologics Plasma-derived Therapies Introduction
7.18.4 KM Biologics Revenue in Plasma-derived Therapies Business (2021-2026)
7.18.5 KM Biologics Recent Development
8 Plasma-derived Therapies Market Dynamics
8.1 Plasma-derived Therapies Industry Trends
8.2 Plasma-derived Therapies Market Drivers
8.3 Plasma-derived Therapies Market Challenges
8.4 Plasma-derived Therapies Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer